Search clinical trials for: foretinib (formerly GSK1363089 or XL880)

Total 14 results

GlaxoSmithKline

Completed

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Carcinoma, Renal Cell

United States
GlaxoSmithKline

Completed

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Neoplasms, Head and Neck

United States
GlaxoSmithKline

Completed

Study of GSK1363089 in Metastatic Gastric Cancer

Neoplasms, Gastrointestinal Tract

United States
GlaxoSmithKline

Completed

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Solid Tumours
Genentech, Inc.

Completed

A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

Healthy Volunteer

United States
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion...

Recruiting

Bleeding In Thrombocytopenia Explained (BITE)

Hemorrhage | Hematologic Neoplasms | Bleeding | Platelet Transfusion

Netherlands
TaiMed Biologics Inc.
Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research Center

Completed

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108)

Prevention of Infection With HIV-1

United States
Amgen
Merck Sharp & Dohme LLC

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (HARBOUR)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

United States, Germany, Spain, Australia, Netherlands, France
Fudan University
Henan Cancer Hospital

Completed

Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Chemotherapy Effect

China
Cancer Research UK

Completed

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Breast Cancer | Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United Kingdom
Noven Therapeutics

Completed

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Hot Flashes

United States
Noven Therapeutics

Completed

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women (N30-005)

Postmenopausal Symptoms

United States
Noven Therapeutics

Completed

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) (N30-003)

Postmenopausal Symptoms

United States
Noven Therapeutics

Completed

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Hot Flashes

United States

3

Subscribe